Publication: Cancer Discovery. 6(10): 1106-1117.
Published Date: August 2016
Explores efficacy and safety of BCL-2 inhibitor (venetoclax) for eliminating chemotherapy-resistant leukemia stem cells acute myelogenous leukemia (AML).
Venetoclax monotherapy demonstrated clinical activity in patients with AML (relapsed/refractory or unfit for intensive chemotherapy) with a tolerable safety profile in this phase II study. The authors identified predictive markers of a response consistent with BCL-2 dependence were identified. Clinical and preclinical findings provided a compelling rationale to evaluate venetoclax combined with other agents in AML.